This is a valid preclinical model, that has been widely used for the development of approved drugs, which are effective in the therapy of Crohn’s disease and ulcerative colitis, such as anti-TNF-α and anti-α4β7-integrin antibodies and probiotics [36, 37, 38] for example. Here, TNF is linked to ulcerative colitis.